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85% of younger patients. The vast majority of cT3 patients received
radiotherapy in combination with hormonal therapy, regardless of age.
However, in the eldest patients (80 years) hormonal monotherapy was
applied most frequently (>60%). In the patients with cT4/N+/M+ PC, the
use of hormonal therapy as monotherapy increased strongly with
increasing age. The 5-year relative survival decreased with increasing
age: 92% for the patients aged <70 years, 87% for patients aged 70-80
years, and 68% for patients aged 80 years. The 5-year relative sur-
vival of low stage PC appeared to be similar for patients aged <70
years versus 70, whereas the survival of advanced PC (T3) was
worse for older patients: 5-year relative survival is 97% versus 91% for
the cT3 patients and 53% versus 43% for the cT4/N+/M+, respectively
for patients aged <70 years versus 70 years.
CONCLUSIONS: Elderly men with PC are more often diag-
nosed with advanced disease, possibly as a result of patients’ or doc-
tors’ delay. After adjusting for disease stage, older patients have a
worse prognosis than younger patients. Further research should eluci-
date whether elderly PC patients are treated optimally while taking the
increased life expectancy and the trade-off between the beneficial ef-
fects and adverse events of the treatments into account.
Source of Funding: none
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INTRODUCTION AND OBJECTIVES: Global prostate cancer
incidence rates are lower in Asian men than white men. To what degree
this relates to less aggressive screening in Asian men or inherent dif-
ferences by race remains to be determined. Our aim was to determine
whether Asian race was associated with lower prostate cancer diag-
nosis in a study of all men who received prostate-specific antigen (PSA)
screening and systematic prostate biopsies independent of PSA levels.
METHODS: REDUCE was a 4-year, multicenter, randomized,
double-blind, placebo-controlled study that followed biopsy-negative
men with protocol-dictated PSA-independent biopsies at 2- and 4-
years. Eligible men were aged 50-75 years, had serum PSA between
2.5-10 ng/mL, and a prior negative prostate biopsy. We tested the as-
sociation between race and receipt of prostate biopsy as well as race
and prostate cancer diagnosis using multivariable logistic regression.
RESULTS: Of 8,122 men in REDUCE, 7,296 were of white or
Asian race and had complete data for analysis. Asian men had lower
BMI (24.8 vs 26.9, p<0.001) and smaller prostate volumes (34.2 vs 43.4
cc, p<0.001) but were similar in baseline age, PSA, family history of
prostate cancer, and digital rectal exam findings compared to white
men. There was no difference in rate of receiving a prostate biopsy
between Asian and white men (p¼0.634). After adjusting for various
clinical and demographic characteristics, Asian men were less likely to
be diagnosed with cancer during the 4-year study compared to white
men (OR 0.56, p¼0.011). When testing for differences in cancer grade,
Asian race was significantly associated with decreased risk of low-
grade cancer compared to white race (OR 0.43, p¼0.016). This risk
reduction was also observed for high-grade cancer (OR 0.63, p¼0.290)
though the association was not statistically significant.
CONCLUSIONS: Among men with a negative pre-study biopsy
who all underwent biopsies largely independent of PSA, Asian race was
associated with reduced risk of prostate cancer diagnosis. These data
suggest less screening among Asian men globally cannot completely
explain the lower risk of prostate cancer among Asian men. Further
studies are needed to explore the inherent differences attributed by race
in prostate cancer diagnosis.
Source of Funding: This study was supported by
GlaxoSmithKline (GSK).
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INTRODUCTION AND OBJECTIVES: Decision aids (DAs)
support shared decision making for the treatment of localized prostate
cancer by providing balanced evidence based information, eliciting
preferences and by structuring the decision making process. Studies
have shown that the use of a DA may increase minimal/non-invasive
treatment options. However, the current literature is uncertain about the
effect on treatment choice in localized prostate cancer using DAs. Our
objective is to study the effect of a preference sensitive web based DA
on treatment decision making.
METHODS: A randomized cluster controlled trial was per-
formed among 18 hospitals between 2014-2016. In the intervention
arm (nine hospitals) the DA was offered following diagnosis (N¼332).
Patients in the control arm (another nine hospitals) received care and
information as usual (N¼128). After treatment decision-making but
before treatment start, patients in both arms received a questionnaire
measuring treatment choice, decisional conflict and knowledge. An-
alyses were performed using t-tests, ANOVA and Pearson
correlations.
RESULTS: Response rate was 72% (intervention N¼273,
control N¼109). No differences were found in PSA and Gleason score
between groups. The decision aid led to more patients choosing active
surveillance (AS) in comparison with standard information (28% vs.
17%, P¼0.03). In the control arm we found significantly more external
beam radiotherapy (EBRTx) (16% vs 8%, P¼0.02) and brachytherapy
(BT) ( 33% vs. 19%, P¼0.005). No differences were found in decisional
conflict and knowledge. One in five patients indicated to prefer a deci-
sion aid in a paper form instead of online.
CONCLUSIONS: Patients made different treatment choices
after DA use. The online DA supported shared decision making and this
may lead to significantly more AS. More radiotherapy was found in the
control arm. The decision aid did not lead to more decisional conflict.
However, a minority of the patients prefers a paper form of the decision
aid. The most optimal DA form needs to be determined. We currently
collect post-treatment measures to determine regret and treatment
satisfaction levels.
Source of Funding: none
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INTRODUCTION AND OBJECTIVES: Contemporary treatment
trends for prostate cancer show increased rates of active surveillance.
However, nationwide applicability of these reports is limited. Addition-
ally, the impact of Commission on Cancer facility type on prostate
cancer treatment patterns is unknown.
METHODS: We used the National Cancer Data Base between
2004 and 2013 to identify men diagnosed with prostate cancer. Our
cohort was stratified based on the National Comprehensive Cancer
Network prostate cancer risk-classes. Cochran-Armitage tests evalu-
ated temporal trends. Random effects hierarchical logit models
assessed treatment variation at Commission on Cancer-facility and
institution level.
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